Clinical Trials for Liver Cancer Drug Development
We obtained orphan drug designation (ODD) from the U.S. FDA for liver cancer in 2018, and received approval for Phase II clinical trials from the FDA in 2021. We also secured approval for Phase II clinical trials from Taiwan's Ministry of Health and Welfare (TFDA) and partnered with 13 medical centers in Taiwan.
READ MORE
Head neck cancer new drug development progress
Clinical trial for head neck cancer (Project ID: LUKACT-01-01; Project title: Study on the use of activated T cells for the treatment of locally advanced head neck squamous cell carcinoma after surgery section and combined radiotherapy and chemotherapy) was approved by TFDA in 2018.
READ MORE
